ISPC Quote, Financials, Valuation and Earnings

Delcath Systems, Inc. has a net margin of -2608.44% compared to iSpecimen, Inc.'s net margin of 4.04%. iSpecimen, Inc.'s return on equity of -430.7% beat Delcath Systems, Inc.'s return on equity of 1.59%.

iSpecimen, Inc. has a consensus price target of --, signalling upside risk potential of 12315.93%. On the other hand Delcath Systems, Inc. has an analysts' consensus of $22.31 which suggests that it could grow by 128.07%. Given that iSpecimen, Inc. has higher upside potential than Delcath Systems, Inc., analysts believe iSpecimen, Inc. is more attractive than Delcath Systems, Inc..

iSpecimen, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Delcath Systems, Inc. has a beta of 0.410, suggesting its less volatile than the S&P 500 by 59.033%.

iSpecimen, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Delcath Systems, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. iSpecimen, Inc. pays -- of its earnings as a dividend. Delcath Systems, Inc. pays out -- of its earnings as a dividend.

iSpecimen, Inc. quarterly revenues are $106.6K, which are smaller than Delcath Systems, Inc. quarterly revenues of $20.6M. iSpecimen, Inc.'s net income of -$2.8M is lower than Delcath Systems, Inc.'s net income of $830K. Notably, iSpecimen, Inc.'s price-to-earnings ratio is -- while Delcath Systems, Inc.'s PE ratio is 1,124.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for iSpecimen, Inc. is 0.42x versus 4.66x for Delcath Systems, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Chrome Holding Co. has a net margin of -2608.44% compared to iSpecimen, Inc.'s net margin of -93.74%. iSpecimen, Inc.'s return on equity of -430.7% beat Chrome Holding Co.'s return on equity of -453.89%.

iSpecimen, Inc. has a consensus price target of --, signalling upside risk potential of 12315.93%. On the other hand Chrome Holding Co. has an analysts' consensus of -- which suggests that it could fall by -40.57%. Given that iSpecimen, Inc. has higher upside potential than Chrome Holding Co., analysts believe iSpecimen, Inc. is more attractive than Chrome Holding Co..

iSpecimen, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Chrome Holding Co. has a beta of 2.154, suggesting its more volatile than the S&P 500 by 115.41%.

iSpecimen, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Chrome Holding Co. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. iSpecimen, Inc. pays -- of its earnings as a dividend. Chrome Holding Co. pays out -- of its earnings as a dividend.

iSpecimen, Inc. quarterly revenues are $106.6K, which are smaller than Chrome Holding Co. quarterly revenues of $25.4M. iSpecimen, Inc.'s net income of -$2.8M is higher than Chrome Holding Co.'s net income of -$23.8M. Notably, iSpecimen, Inc.'s price-to-earnings ratio is -- while Chrome Holding Co.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for iSpecimen, Inc. is 0.42x versus 0.53x for Chrome Holding Co.. Usually stocks with elevated PS ratios are considered overvalued.

RadNet, Inc. has a net margin of -2608.44% compared to iSpecimen, Inc.'s net margin of 2.66%. iSpecimen, Inc.'s return on equity of -430.7% beat RadNet, Inc.'s return on equity of 1.82%.

iSpecimen, Inc. has a consensus price target of --, signalling upside risk potential of 12315.93%. On the other hand RadNet, Inc. has an analysts' consensus of $91.71 which suggests that it could grow by 16.7%. Given that iSpecimen, Inc. has higher upside potential than RadNet, Inc., analysts believe iSpecimen, Inc. is more attractive than RadNet, Inc..

iSpecimen, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison RadNet, Inc. has a beta of 1.485, suggesting its more volatile than the S&P 500 by 48.541%.

iSpecimen, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. RadNet, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. iSpecimen, Inc. pays -- of its earnings as a dividend. RadNet, Inc. pays out -- of its earnings as a dividend.

iSpecimen, Inc. quarterly revenues are $106.6K, which are smaller than RadNet, Inc. quarterly revenues of $522.9M. iSpecimen, Inc.'s net income of -$2.8M is lower than RadNet, Inc.'s net income of $13.9M. Notably, iSpecimen, Inc.'s price-to-earnings ratio is -- while RadNet, Inc.'s PE ratio is 1,513.25x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for iSpecimen, Inc. is 0.42x versus 3.02x for RadNet, Inc.. Usually stocks with elevated PS ratios are considered overvalued.